Synribo Approved to Treat Rare Leukemia
Latest Cancer News
FRIDAY, Oct. 26 (HealthDay News) -- Synribo (omacetaxine mepesuccinate) has been approved by the U.S. Food and Drug Admnistration to treat a rare blood and bone marrow disease called chronic myelogenous leukemia (CML).
Some 5,430 people will be diagnosed with CML this year, the U.S. National Institutes of Health estimates. Synribo has been sanctioned to treat cases in which two other specific anti-cancer drugs have failed to stop CML's progression, the FDA said Friday in a news release.
Synribo is designed to be injected twice daily in different regimens for a number of consecutive days until white blood cell counts normalize, the agency said.
Synribo is marketed by the Israeli drug maker Teva Pharmaceuticals, with U.S. headquarters in Frazer, Pa.
-- Scott Roberts
Copyright © 2012 HealthDay. All rights reserved.
Get the latest health and medical information delivered direct to your inbox FREE!